Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ECOG performance status of 0, 1, or 2
Life expectancy of at least 12 weeks
Histologic documentation of previously treated t(4;14)-positive multiple myeloma for which no effective standard therapy exists
You may not be if
Prior use of any monoclonal antibody before study treatment
Treatment with radiotherapy, thalidomide, lenalidomide, bortezomib, any chemotherapeutic agent, or treatment with any other investigational anti-cancer agent within 4 weeks of study treatment
Completion of autologous stem cell transplant within 6 months prior to study treatment
Prior allogeneic stem cell transplant
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
Evidence of significant, uncontrolled concomitant diseases, including significant cardiovascular disease or pulmonary disease
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at screening or any recent major episode of infection requiring treatment with IV antibiotics or hospitalization prior to study treatment
Recent major surgery (prior to study treatment), other than for diagnosis
Presence of positive test results for Hepatitis B or Hepatitis C
Known history of HIV seropositive status
Women who are pregnant or lactating
Childbearing potential without agreement to use effective form of contraception for the duration of the study
